AI-generated analysis. Always verify with the original filing.
CorMedix Inc. released an updated investor presentation (Exhibit 99.1) and reaffirmed full-year 2027 DefenCath sales guidance of $100 million to $140 million, correcting an inadvertent $100 million to $125 million statement from its March 5, 2026 earnings call. The presentation provides 2026 revenue guidance of $300–320 million and adjusted EBITDA guidance of $100–125 million.
Event Type
Disclosure
Voluntary
Variant
8-K
(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or other
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 CorMedix Corporate Presentation 104 Cover Page Interactive Data File (embedded withi